Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
MHLW to Set Prerequisites for Patients, Physicians to Optimize Innovative Drug Use: Pharma Bureau Chief
The Ministry of Health, Labor and Welfare (MHLW) plans to draw up guidelines that specify prerequisites for target patients and physicians for innovative drugs, a senior MHLW official says - giving shape to a government pledge made in June to…
To read the full story
Related Article
- Chuikyo OKs Plan to Compile “Optimal Use Guidelines,” Beginning with Opdivo, Repatha
July 28, 2016
- MHLW to Canvass Drug Makers’ Opinions on Real-World Roles of “3 Key Officers”: Pharma Safety Head
July 27, 2016
- MHLW Pharma Bureau Chief Wants to Discuss Roles of Drug Makers’ 3 Key Officers
July 15, 2016
- MHLW’s Feat to Link Drug Review and Reimbursement Policies Put to Test with “Expensive Drugs”
June 28, 2016
REGULATORY
- MHLW Sets FY2027 Budget Priorities for Drug Discovery, Advanced Medicine
July 28, 2026
- Japan Enacts Revised Immunization Act, Opens Way for RSV Antibodies under NIP
July 27, 2026
- PMDA Sees Drop in Japan-China Bilateral Regulatory Exchanges
July 27, 2026
- MHLW to Hear Patient Groups on OTC-Like Drug Charge Exemptions
July 27, 2026
- Japan to Clarify Non-Clinical Data Waivers for Repurposed Drugs, Ease Sakigake Rules
July 24, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…